Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kamada Ltd (KMDA)

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,627
  • Shares Outstanding, K 44,520
  • Annual Sales, $ 133,250 K
  • Annual Income, $ 17,140 K
  • 60-Month Beta 1.02
  • Price/Sales 1.78
  • Price/Cash Flow 10.83
  • Price/Book 1.31
Trade KMDA with:

Options Overview

Details
  • Implied Volatility 109.06%
  • Historical Volatility 15.35%
  • IV Percentile 58%
  • IV Rank 33.14%
  • IV High 303.49% on 11/06/20
  • IV Low 12.68% on 05/14/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 5,457

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.03
  • Low Estimate 0.02
  • Prior Year 0.15
  • Growth Rate Est. (year over year) -80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.17 +3.68%
on 08/19/21
5.52 -2.90%
on 09/07/21
-0.11 (-2.01%)
since 08/13/21
3-Month
5.17 +3.68%
on 08/19/21
6.47 -17.16%
on 06/25/21
-0.45 (-7.75%)
since 06/15/21
52-Week
5.17 +3.68%
on 08/19/21
9.04 -40.71%
on 09/17/20
-3.39 (-38.74%)
since 09/15/20

Most Recent Stories

More News
3 Under the Radar Pharmaceutical Stocks to Add to Your Watchlist

The pharmaceutical industry is expected to attract significant investor attention in the coming months as the demand for vaccines and therapies continues to soar with the resurgence of COVID-19 cases globally....

CPRX : 5.00 (+2.04%)
KMDA : 5.36 (+0.75%)
OPNT : 21.80 (+12.08%)
New Strong Sell Stocks for August 25th

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

CHRS : 15.79 (-1.80%)
KMDA : 5.36 (+0.75%)
STIM : 6.55 (+0.46%)
PHUN : 1.0100 (+1.13%)
BEEM : 29.47 (+4.95%)
Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 5.36 (+0.75%)
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2021.

KMDA : 5.36 (+0.75%)
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open...

KMDA : 5.36 (+0.75%)
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KMDA : 5.36 (+0.75%)
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

GILD : 71.76 (+1.86%)
RGEN : 296.40 (+0.65%)
TECH : 529.64 (+3.87%)
KMDA : 5.36 (+0.75%)
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

RGEN : 296.40 (+0.65%)
TECH : 529.64 (+3.87%)
KMDA : 5.36 (+0.75%)
BPMC : 103.73 (+3.70%)
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

VRTX : 188.86 (+0.24%)
BAYRY : 13.4600 (-0.15%)
KMDA : 5.36 (+0.75%)
CRSP : 117.26 (+0.83%)
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children

The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.

VRTX : 188.86 (+0.24%)
RGEN : 296.40 (+0.65%)
TECH : 529.64 (+3.87%)
KMDA : 5.36 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

3rd Resistance Point 5.54
2nd Resistance Point 5.48
1st Resistance Point 5.42
Last Price 5.36
1st Support Level 5.30
2nd Support Level 5.24
3rd Support Level 5.18

See More

52-Week High 9.04
Fibonacci 61.8% 7.56
Fibonacci 50% 7.11
Fibonacci 38.2% 6.65
Last Price 5.36
52-Week Low 5.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar